



Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

April 27, 2023 12:30 PM EDT

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- [Prelude Therapeutics Incorporated](#) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences.

Details are as follows:

- **H. C. Wainwright BioConnect Investor Conference at Nasdaq**

Kris Vaddi, Ph.D., Chief Executive Officer will participate in a fireside chat on Tuesday, May 2, at 1:30 p.m. ET. The live webcast is available [here](#). The Company will also host one-on-one investor meetings during the day.

- **Bank of America Securities 2023 Healthcare Conference**

Jane Huang, MD, President and Chief Medical Officer and Laurent Chardonnet, Chief Financial Officer, will conduct one-on-one meetings on Wednesday, May 10 and Thursday May 11. Dr. Huang will participate in a fireside chat on May 10 at 4:20 p.m. PT/7:20 p.m. ET. The live webcast will be available [here](#), and will be available for replay until August 11, 2023.

- **JMP Securities Life Sciences Conference**

Dr. Vaddi and Mr. Chardonnet will conduct one-on-one meetings on Monday, May 15 and Tuesday May 16 and Dr. Vaddi will participate in a fireside chat at 12 noon ET, on May 15. The live webcast is available [here](#) and will be available for replay for 90 days.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's diverse pipeline is comprised of highly differentiated, potentially best-in-class or first-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789, an IV administered, potent and highly selective SMARCA2 degrader.

For more information, visit our [website](#) and follow us on [LinkedIn](#) and [Twitter](#).

Investor Contact:

Lindsey Trickett
Vice President, Investor Relations
240.543.7970
ltrickett@preludetx.com

Media Contact:

Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com